A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

1,036

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide

subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day

DRUG

insulin lispro

titrated based on pre-meal glucose level; three times a day

DRUG

Metformin

DRUG

Insulin/ Glargine

Trial Locations (95)

Unknown

Research Site, Buenos Aires

Research Site, Caba

Research Site, Capital Federal

Research Site, Ciudad Autonoma de Buenos Aire

Research Site, Ciudad de Buenos Aires

Research Site, Corrientes

Research Site, Rosario

Research Site, San Rafael

Research Site, Arlon

Research Site, Bonheiden

Research Site, Edegem

Research Site, Merksem

Research Site, Tallinn

Research Site, Tartu

Research Site, Helsinki

Research Site, Oulu

Research Site, Vantaa

Research Site, Angers

Research Site, Auxerre

Research Site, Bar-le-Duc

Research Site, Douai

Research Site, La Roche-sur-Yon

Research Site, La Rochelle

Research Site, Le Creuzot

Research Site, Lille

Research Site, Marseille

Research Site, Montpellier

Research Site, Nanterre

Research Site, Pessac

Research Site, Rennes

Research Site, Strasbourg

Research Site, Toulouse

Research Site, Vénissieux

Research Site, Bad Lauterberg im Harz

Research Site, Dippoldiswalde

Research Site, Friedrichsthal

Research Site, Goch

Research Site, Grevenbroich

Research Site, Hamburg

Research Site, Mainz

Research Site, Saarbrücken

Research Site, Athens

Research Site, Thessaloniki

Research Site, Florence

Research Site, Napoli

Research Site, Olbia

Research Site, Perugia

Research Site, Trieste

Research Site, Verona

Research Site, Aguascalientes

Research Site, Cuernavaca

Research Site, Mexico City

Research Site, Monterrey

Research Site, Almere Stad

Research Site, Amsterdam

Research Site, Beek

Research Site, Groningen

Research Site, Heerlen

Research Site, Hoogeveen

Research Site, Sittard-Geleen

Research Site, The Hague

Research Site, Coimbra

Research Site, Lisbon

Research Site, Portugal

Research Site, Hato Rey

Research Site, Bucharest

Research Site, Cluj-Napoca

Research Site, Constanța

Research Site, Craiova

Research Site, Oradea

Research Site, Ploieşti

Research Site, Arkhangelsk

Research Site, Rostov-on-Don

Research Site, Saint Petersburg

Research Site, Seoul

Research Site, Ulsan

Research Site, Wŏnju

Research Site, A Coruña

Research Site, Alicante

Research Site, Barcelona

Research Site, Dos Hermanas

Research Site, Santander

Research Site, Valencia

Research Site, Halmstad

Research Site, Karlstad

Research Site, Lund

Research Site, Malmo

Research Site, Solna

Research Site, Stockholm

Research Site, Umeå

Research Site, Bournemouth

Research Site, Ipswich

Research Site, Leicester

Research Site, Penarth

Research Site, Wakefield

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY